Navigation Links
GenVec Achieves Second Milestone in Collaboration
Date:12/6/2011

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

"Completing this milestone reflects sustained progress and we look forward to reaching additional milestones with Novartis in this very exciting program," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

About the CollaborationIn January 2010, GenVec entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the agreement, if certain clinical, regulatory, and sales milestones are met, GenVec is eligible to receive up to $213.6 million, including upfront and milestone payments in addition to royalties on future sales.

In August 2010, we entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss a
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Applied DNA Sciences, Inc. (OTCQB: ... and product authentication solutions, will host a conference call ... third quarter results. The Quarterly Report on Form 10Q ... of the day on Monday August 11, 2014. ... conference call beginning at 9:00 A.M. Eastern Daylight Time ...
(Date:8/1/2014)... , Aug. 1, 2014 Research ... "The World Market for Flow Cytometry in ... http://photos.prnewswire.com/prnh/20130307/600769 ... are now an important component of advanced IVD ... instruments for cancer diagnostics, but their newer clinical ...
(Date:8/1/2014)... , Aug. 1. 2014 As one of ... 2014 AACC Annual Meeting & Clinical Lab Expo is ... patient care are introduced to the healthcare world. This ... Expo,s 650 exhibitors will include the latest diagnostic technology ... Advances in smartphones and biosensors have enabled the development ...
(Date:8/1/2014)... -- One of the major revolutions taking place in ... the practice of using genomic and other molecular analyses ... Personalized diagnostics—laboratory analyses that inform the practice of personalized ... This fall, AACC ,s first ever virtual ... exciting field and the novel technologies driving it forward, ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3The World Market for Flow Cytometry in IVD Applications 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2
... (Nasdaq: SQNM ) today announced that Ronald ... development, will present an overview of the company at ... http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) ... Healthcare Conference Location: The Palace Hotel, New ...
... 2, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... LOUIS, Sept. 2 Sigma Life Science, the innovative ... (Nasdaq: SIAL ), today announced the global ... lines. This new product range combines Sigma,s proprietary CompoZr ... Company,s extensive experience in gene silencing, to offer innovative ...
Cached Biology Technology:Sequenom to Present at Two Financial Conferences in September 2Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 2Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 3Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 4Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 5Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 6Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 7Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 8Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 9Sigma® Life Science Enters Genetically Modified Cell Market 2Sigma® Life Science Enters Genetically Modified Cell Market 3Sigma® Life Science Enters Genetically Modified Cell Market 4
(Date:8/1/2014)... of phloem, the conductive tissue through which plants transport ... cylindrical cells are capped at one end by a ... which in turn form a network throughout a plant,s ... cells which play an important role in carbon sequestration, ... their differentiation," says Professor Yk Helariutta from the Institute ...
(Date:8/1/2014)... Aug. 1, 2014  LiveScan Service Provider Binary Biometrics is pleased ... a result, Binary Biometrics will improve its mobile service capabilities and add more ... County and service several new cities such as, but not limited ... DeLand , Deltona , Edgewater ... New Smyrna Beach , Oak Hill , ...
(Date:7/31/2014)... Foundation (NSF), counters a widely-held scientific view that ... that certain Arctic lakes store more greenhouse gases ... The study, published this week in the journal ... occur as permafrost thaws and creates surface depressions ... was previously frozen land into lakes. , The ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3Certain Arctic lakes store more greenhouse gases than they release 2
... The 2009 American Society for Microbiology Public ... reporters Michael Berens and Ken Armstrong for their ... (MRSA) in Washington State hospitals. The series, entitled ... the spread of epidemics such as MRSA infection ...
... diseases that starve eye tissue and nerves of oxygen ... researchers at Oak Ridge National Laboratory, the University of ... technique uses a new class of smart prosthetic implants ... oxygen because of restricted blood flow. This condition occurs ...
... high among people born in Scotland or Ireland compared with ... Research, conducted by the University of Edinburgh and the Office ... but living in England and Wales had similar ... The findings showed too that people born in parts of ...
Cached Biology News:Seattle Times reporters win ASM public communications award 2ORNL, Southern Cal set sights on preventing blindness 2Scots and Irish at greater risk of drink-related death, study shows 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Reacts with methylated DNA from plants and vertebrates...
...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: